In 2021, research led by Ryan Flynn, MD, Ph.D., and his mentor, Nobel laureate Carolyn Bertozzi, Ph.D., opened a new chapter ...

Researchers show that glycoRNAs, uncovered by the lab of Nobel Laureate, Carolyn Bertozzi, can be used to fight cancer.

The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

Leukemia patients who enroll in LLS's PedAL screening trial and are found to have certain alterations will be directed to receive ziftomenib in a Phase I study.

“This NDA submission brings us one step closer to our goal of advancing ziftomenib to market as a new therapeutic option for adult patients with R/R NPM1-m AML, a devastating disease for which ...

Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced ...

Targeting the NPM1 protein AML, a rapidly progressive blood cancer, has been difficult to target therapeutically because many of its driving pathways are also essential for non-cancerous cells ...